Research Data Policy

AROGYA · RESEARCH DATA POLICY

Arogya: Journal of Public Health and Health Services in Indonesia encourages transparency, traceability, and responsible reuse of research data. Data availability must always be balanced with privacy, confidentiality, consent, research ethics, third-party rights, and applicable legal requirements.

  • Data Availability Statement required
  • Open where safe and ethical
  • Patient data must be protected
  • Controlled access is permitted
  • Data sources must be credited

1. Scope and purpose

This policy applies to authors and all contributors to manuscripts submitted to Arogya. It covers primary and secondary data used to produce an article's findings, including quantitative and qualitative data, survey data, laboratory data, observational data, clinical trial data, research instruments, protocols, analysis code, and other relevant supporting materials.

The policy aims to help readers assess, verify, and—where permitted—reuse the evidence underlying research findings, while protecting the rights and safety of participants, patients, communities, data owners, and responsible institutions.

2. Data stewardship and sharing principles

Transparency and traceability

Authors should explain which data underpin the findings, where the data came from, how they were collected or obtained, and how readers may access them or understand the reasons for restriction.

Responsible openness

Data should be shared openly when consent, ethics, privacy, rights, security, and applicable law permit. Openness must not override confidentiality or create an unacceptable risk of re-identification.

Protection and minimisation

Only data necessary for the research purpose and verification of findings should be collected or shared. Direct and indirect identifiers must be protected in proportion to the risk.

Credit and lawful reuse

Data created or collected by others must be used in accordance with permissions, data-owner terms, relevant consent, and licences. Data sources must be properly acknowledged and cited.

Arogya encourages the FAIR principles—Findable, Accessible, Interoperable, and Reusable—where appropriate to the context and required protections. FAIR does not mean that every dataset must be publicly available; access may require authentication or authorisation.

3. Author responsibilities

Every manuscript must include a Data Availability Statement, including when data cannot be shared or the statement is not applicable. The statement should appear in the section specified by the manuscript template or near the end of the article before the references, as instructed by the journal.

  • Identify the data underlying the article's main findings and state whether those data are available, restricted, or not applicable.
  • When data are available, provide the repository name, persistent link, DOI, accession number, or a clear access procedure. Check that links work and resolve to the correct data.
  • When access is by request, identify the authorised recipient of requests, eligibility criteria, permitted purposes, required documents or approvals, and the submission procedure.
  • Explain restrictions arising from participant consent, ethics approval, personal data protection, data-use agreements, intellectual property, or data-owner requirements.
  • Ensure that data, documentation, code, and supplementary materials are consistent with the reported methods and results. Any dataset changes or corrections must be documented.
  • Obtain all necessary permissions before sharing third-party data. Online accessibility does not automatically mean that data may be redistributed or reused without restriction.
  • Do not upload identifiable patient or participant data to the article page, supplementary files, or a public repository.
Important: Arogya does not act as the custodian or repository for authors' research data. Authors are responsible for storage, security, permissions, access management, and the continued availability of any dataset they identify in their statements.

4. Minimum contents of a Data Availability Statement

A Data Availability Statement should be concise, specific, and verifiable. When data are shared openly or through controlled access, the statement should identify:

  1. the type or parts of the data available, including whether de-identified individual-level data will be shared;
  2. related documents available, where applicable, such as the research protocol, statistical analysis plan, data dictionary, instruments, or analysis code;
  3. the location, repository, DOI, accession number, or request mechanism;
  4. when the data will become available and, where relevant, the duration of access;
  5. who may request or access the data, for what purposes, through which procedure, and subject to which conditions.

For clinical trials covered by ICMJE policy, the data sharing statement must meet ICMJE-specific elements, including the status of sharing de-identified individual participant data, the data and documents available, the timing and duration of access, and the access criteria.

5. Access options and exceptions

Open access

Datasets may be made publicly accessible through an appropriate repository when permissions, consent, ethics requirements, and law allow. Provide metadata, a reuse licence, and a persistent identifier where available.

Controlled access

Data may be accessed only by eligible applicants through a request and approval process managed by the responsible party. Conditions may include ethics approval, a data-use agreement, or a security plan.

Data cannot be shared

Data must not be shared when disclosure would breach privacy, consent, law, third-party rights, security, or ethics requirements. Authors should explain the specific reason and, where possible, provide safe summaries or metadata.

Acceptable reasons for restriction may include direct or indirect re-identification risks, very small groups, sensitive health data, restrictions in consent forms or ethics protocols, confidentiality agreements, data-owner rights, or legal prohibitions. Restrictions should be proportionate and explained transparently.

When the full dataset cannot be released, authors are encouraged to provide a safe alternative, such as aggregate data, validated synthetic data that do not disclose the original records, a data dictionary, protocol, analysis code, or supervised access. Such alternatives must not be presented as equivalent to the original data.

6. Health data protection, privacy, and ethics

Health data and information are classified as specific Personal Data under Indonesia's Law No. 27 of 2022 on Personal Data Protection. Medical records and patients' private health information are also protected by health-sector regulations. Accordingly, health data sharing requires particular care.

  • Do not disclose names, medical record numbers, addresses, phone numbers, identity numbers, full dates of birth, facial photographs, or other direct identifiers.
  • Review indirect identifiers and combinations of variables that may permit re-identification, including small groups, specific locations, event dates, or rare conditions.
  • Removing names alone may not be sufficient. Authors must assess re-identification risks and apply masking, grouping, reduced precision, or appropriate access restrictions.
  • Ensure that sharing is consistent with participant consent, the research protocol, ethics committee decisions, institutional requirements, and a lawful basis for personal data processing.
  • Where data are obtained from a healthcare facility, ensure that the required authority and permissions have been obtained from the facility or relevant data controller.
  • Data collected for a specific purpose must not be repurposed without an appropriate legal basis, permission, or consent.
  • Use secure transfer and storage methods. Limit access to people who need it and document terms for further use.
Do not upload identifiable patient data to a public repository. When there is uncertainty about whether a dataset is sufficiently safe to share, use controlled access or do not share individual-level data. Authors should consult the ethics committee, institution, data protection officer, or responsible data controller.

A statement that a dataset has been anonymised does not replace compliance with ethics approval, participant consent, or applicable law. Arogya may request information about data governance and safeguards when necessary to assess a manuscript.

7. Specific requirements for clinical trials

For clinical trials that begin enrolling participants on or after 1 January 2019 and are covered by ICMJE policy, authors must include a data sharing plan in the trial registration and a data sharing statement in the manuscript. Any change to the plan after registration should be reflected in the manuscript statement and updated in the relevant registry record.

The statement must explain whether de-identified individual participant data (including data dictionaries) will be shared; which data will be shared; which supporting documents will be available; when and for how long the data will be available; and who may access the data, for which types of analyses, and through what mechanism.

Authors conducting secondary analyses must properly cite the dataset source, include a persistent identifier where available, comply with the data-use terms, and explain how their analysis differs from previous publications.

8. Repositories, documentation, and data citation

Arogya recommends institutional repositories, subject-specific repositories, or general-purpose repositories with clear governance and access conditions. Select a repository that is appropriate for the sensitivity of the dataset and institutional policy. Repository examples are not exclusive endorsements and do not mean that every dataset is suitable for deposit there.

  • Use a persistent identifier, such as a DOI or accession number, where available.
  • Provide sufficient metadata and documentation to explain variables, units, definitions, collection methods, period, population, and data limitations.
  • Include a data dictionary, instrument, protocol, or analysis code where relevant and permitted for sharing.
  • Clearly state the licence or terms for reuse. Do not apply an open licence if you do not have the rights to grant it.
  • Cite datasets in the reference list or an appropriate reference section, identifying the data creator, title, repository, year, and persistent DOI/URL where available.

FAIR means that data and metadata should be made findable, accessible, interoperable, and reusable. Access may still be restricted through authentication or authorisation when necessary to protect individuals and legitimate interests.

9. Editorial assessment and suspected misconduct

Editors may request further explanations, documentation, protocols, evidence of approval, repository information, or restricted access to underlying data to assess the consistency and reliability of a manuscript. Such requests must respect applicable ethics, privacy, rights, and legal restrictions.

Reviewers must not request or receive personal data that identify patients or participants. Data supplied for editorial assessment must be shared securely and used only for manuscript evaluation; such access does not make the data publicly available.

Suspected fabrication, falsification, manipulation, concealment of data restrictions, unauthorised data use, or a false data availability statement will be handled under Arogya's publication ethics policy and relevant guidance. Depending on the evidence and seriousness, actions may include requests for clarification, a pause in editorial decisions, manuscript rejection, correction, or appropriate post-publication action.

10. Data Availability Statement examples

Use the following examples as templates and adapt them to the actual circumstances of the research. Replace all bracketed text. Do not state that data are available unless the link, permission, or access process is genuinely in place.

A. Data available in an open repository

“The data supporting the findings of this study are openly available in [repository name] at [persistent DOI/URL]. The dataset includes [brief description of data] and may be reused under the [licence name] licence.”

B. Data available by request under controlled access

“The data supporting the findings of this study are not publicly available because of [specific reason, such as participant privacy protection or ethics approval conditions]. Access requests may be submitted to [role/unit or data steward] through [official mechanism/contact]. Requests will be considered from applicants meeting [criteria], for [permitted purposes], after obtaining [ethics approval/data-use agreement/other required permission].”

C. Data cannot be shared

“The individual-level data used in this study cannot be shared because of [specific legal, privacy, consent, or contractual reason]. This restriction is necessary to protect [relevant party or interest]. Non-identifying aggregate information is presented in the article and/or its supplementary materials.”

D. No new dataset was generated or analysed

“Data availability is not applicable to this article because no new dataset was generated or analysed. This article uses [explain where relevant: a conceptual review, analysis of published documents, or public sources cited in the article].”

E. Data obtained from a third party

“The data analysed in this study were obtained from [data source/owner]. The authors are not permitted to redistribute or independently archive the data because of [access/licensing terms]. Access may be obtained through [official link or procedure of the data owner], subject to the owner's requirements.”

11. References and guidance

This policy has been prepared with reference to relevant international guidance and Indonesian regulations. Authors remain responsible for complying with the rules and guidance applicable when the research and publication take place.

  1. International Committee of Medical Journal Editors (ICMJE), Recommendations: Clinical Trial Registration and Data Sharing. Specifies elements for clinical trial data sharing statements.
  2. World Health Organization (WHO), Data Principles. Emphasises sharing data when safe and ethical, transparency, security, and privacy protection.
  3. WHO, Sharing and reuse of health-related data for research purposes: policy and implementation guidance (2022).
  4. Law of the Republic of Indonesia No. 27 of 2022 on Personal Data Protection. Health data and information are specific Personal Data.
  5. Minister of Health Regulation No. 24 of 2022 on Medical Records.
  6. Government Regulation No. 28 of 2024 implementing Law No. 17 of 2023 on Health, including provisions concerning patients' private health information.
  7. Wilkinson et al. (2016), The FAIR Guiding Principles for scientific data management and stewardship, Scientific Data, 3, 160018.

This policy applies to all manuscripts submitted to Arogya from its effective date and may be reviewed when relevant ethical guidance, scientific standards, or applicable regulations change.

Arogya: Journal of Public Health and Health Services in Indonesia Published by PT Pustaka Sosio Edukasi · info@pustakaedukasi.com